Skip to content
    JAZZ
    Earnings call· Mar 2026(Q1 FY26)

    Jazz Pharmaceuticals Q1 FY26 earnings call JAZZ

    May 5, 2026 Source

    Executive summary

    Jazz Pharmaceuticals Q1 FY26 — Record Revenue and Zanidatamab Progress Drive Strong Start

    Jazz Pharmaceuticals delivered an exceptionally strong first quarter, marked by record revenues and double-digit growth across its key commercial brands. The company is actively preparing for the potential launch of zanidatamab in HER2-positive GEA following its FDA Priority Review, while also advancing its broader pipeline. With a robust financial position, Jazz remains focused on strategic business development to expand its rare disease portfolio and leverage its existing capabilities.

    Highlights

    5
    • Achieved highest ever first quarter total revenues of $1.1 billion, reflecting more than 19% year-over-year growth.

    • Generated double-digit growth across all promoted brands: Xywav, Epidiolex, Modeyso, and Zepzelca.

    • Reported strong cash flow from operations of over $400 million in the first quarter.

    • Posted robust non-GAAP adjusted EPS of $6.34.

    • FDA accepted sBLA for Ziihera (zanidatamab) in HER2-positive first-line GEA with Priority Review and a PDUFA date of August 25, 2026.

    Concerns

    3
    • Non-GAAP adjusted gross margin declined slightly year-on-year, primarily due to higher sales of products carrying royalties (Zepzelca and Modeyso).

    • Anticipates increased competitive dynamics in the sleep business in the second half of 2026, including high-sodium generics gaining volume and potential entry of new wake-promoting agents.

    • Expects a decline in second-line use of Zepzelca due to competition and fewer Zepzelca naive patients available for treatment.

    Guidance & targets

    7
    CategoryTargetConfidence
    Total Revenue
    $4.25 billion to $4.5 billion
    high materiality
    High
    Ziihera (zanidatamab) GEA Regulatory Approval
    PDUFA date of August 25, 2026
    high materiality
    High
    Ziihera (zanidatamab) GEA Launch
    On or before PDUFA date of August 25, 2026
    high materiality
    High
    EmpowHER trial (zanidatamab) Enrollment Completion
    First half of 2027
    medium materiality
    Medium
    EmpowHER trial (zanidatamab) Top-line Data
    Late 2027 or early 2028
    medium materiality
    Medium
    ACTION trial (Modeyso) Interim Overall Survival Readout
    Late 2026 or early 2027
    medium materiality
    Medium
    HERIZON-GEA trial (zanidatamab) Second Interim OS Analysis
    Midyear
    medium materiality
    High

    Segment performance

    7
    SegmentRevenueYoYQoQMargin
    Xywav
    Strong demand driven by HCPs and patients for low-sodium option, with significant new patient growth, primarily from idiopathic hypersomnia (IH). Remains the #1 branded treatment for narcolepsy and only FDA-approved treatment for IH.
    Net patient adds: 425Active patients: 16,600Volume growth: 12%Payer coverage: >90% commercial lives
    $408M18%
    Epidiolex
    Growth driven by strong underlying demand and volume. Focus on expanding reach in the adult patient population and long-term care settings. Nurse Navigator program continues to improve patient persistency.
    Volume growth: 16%
    $250M15%
    Oncology
    The oncology portfolio demonstrated significant growth, including Ziihera, Modeyso, Zepzelca, and Rylaze.
    45%
    Ziihera (zanidatamab)
    Generated sales from biliary tract cancer (BTC) indication. Expanding into community-based accounts and building readiness for potential launch in GEA, with significant customer overlap between BTC and GEA accounts.
    $13M
    Modeyso
    Strong early performance following its August 2025 launch, reflecting significant unmet need in H3 K27M-mutant diffuse midline glioma. Patients are staying on treatment longer than initially anticipated.
    Patients treated since launch: 500
    $41M
    Zepzelca
    Growth primarily driven by strong uptake in the frontline maintenance setting following FDA approval in combination with Tecentriq. Commercial initiatives are focused on first-line maintenance, with second-line use expected to decrease.
    $101M60%
    Rylaze
    Delivered a strong quarter, though compared to a low Q1 2025. The COGS impact that started in 2024 has been fully realized. Focus continues on ensuring appropriate patients receive Rylaze and growth in AYA.
    $104M10%

    Operational metrics

    12
    Total Revenue Growth
    19%YoY
    Q1 FY26

    Reflects growth across the commercial portfolio.

    Non-GAAP Adjusted EPS
    $6.34
    Q1 FY26

    Robust performance at the bottom line.

    Cash and Investments Balance
    $2.9B
    End of Q1 FY26

    Strong balance sheet providing flexibility for investments and business development.

    Worldwide Revenue Growth (Shipping Weeks Impact)
    2
    Q1 FY26

    Contribution from having 13 shipping weeks for U.S. oncology products in Q1 FY26 versus 12 in Q1 FY25.

    Worldwide Revenue Growth (FX Impact)
    1.5
    Q1 FY26

    Contribution from the significant devaluation of the U.S. dollar.

    Non-GAAP Adjusted SG&A Expense Change
    -$164MYoY
    Q1 FY26

    Decrease primarily due to $172 million litigation settlement expenses recognized in Q1 FY25.

    Non-GAAP Adjusted R&D Expense Change
    $13MYoY increase
    Q1 FY26

    Increase driven by pipeline investments.

    Non-GAAP Adjusted Effective Tax Rate
    slightly lowervs FY26 guidance
    Q1 FY26

    Lower than full year guidance due to discrete items.

    Modeyso Peak Opportunity
    $500M
    Peak

    Confidence in achieving this peak opportunity, incorporating assumption of first-line label.

    Modeyso Duration of Treatment
    longer than initially anticipatedvs trial duration
    Since launch

    Patients are staying on treatment for longer, potential upside for the product.

    Zepzelca Patent Estate
    multiple patents
    Current

    Strong patent estate with ongoing efforts to extend protection.

    Xywav Patent Estate
    robust patents
    Current

    Confidence in overall patent estate, including for IH indication.

    Industry KPIs

    8
    MetricValueDetails
    Peak sales guidance$500MUSD
    Prescription volume425patients
    EPS revenue guidance$4.25B-$4.5BUSD
    Pricing policy impactuncertain
    Therapeutic drug market share#1
    Price volume mix decomposition12% volume growth%
    Geographic regional revenue growthstrong growth
    Business development capacity deal appetite$2.9BUSD

    Deals & partnerships

    1
    Nippon ZokiPartnership for Epidiolex in Japan

    Nippon Zoki will lead regulatory, distribution, and commercial activities for Epidiolex in Japan. Jazz remains the sponsor of the clinical trial.

    Risks & headwinds

    6
    Competitive dynamics in sleep businessSecond half of 2026

    Increased in H2 FY26

    Mitigation: Xywav's unique benefits (low-sodium, IH approval, nighttime efficacy) and Jazz's patient support services are key differentiators.

    High-sodium generics gaining volumeSecond half of 2026

    Expected to build volumes over the course of 2026

    Mitigation: Xywav's low-sodium formulation and strong payer coverage are expected to mitigate impact. Jazz has robust patents for Xywav.

    New wake-promoting agents entering narcolepsy marketSecond half of 2026

    One or more potentially entering

    Mitigation: Orexins are likely complementary to Xywav, which addresses disrupted nighttime sleep directly. Xywav's safety advantage for cardiovascular risk patients is highlighted.

    Decline in Xyrem and high sodium authorized generic revenuesOver the course of 2026

    Expected decline

    Mitigation: As generic high sodium oxybates build their volumes.

    Decline in second-line use of ZepzelcaRest of 2026

    Expected decrease

    Mitigation: Due to competition and fewer Zepzelca naive patients available for treatment. Commercial initiatives are focused on first-line maintenance uptake.

    MFN-related considerations for zanidatamab OUS pricing

    Uncertainty

    Mitigation: GLOBE and GUARD proposals to use ex-U.S. countries for U.S. reference pricing will be taken into account for OUS strategy.

    What to watch in Q2 FY26

    5

    Zanidatamab GEA Regulatory Approval

    August 25, 2026 (PDUFA date)
    CurrentsBLA accepted, Priority Review
    TargetFDA approval

    Why it matters

    FDA approval and subsequent launch of zanidatamab in HER2-positive GEA is a major catalyst for the oncology portfolio and a significant growth driver.

    The FDA recently accepted our sBLA for Ziihera under real-time oncology review and granted priority review with a PDUFA date of August 25, 2026.

    Q&A highlights

    7

    How will physicians sequence HER2 agents if zanidatamab is approved post-HER2, given the lack of data for other products in this setting?

    The EmpowHER trial (303) is designed to definitively evaluate zanidatamab against standard of care in a randomized setting, providing crucial data for sequencing decisions where current data is limited.

    The trial that we're running 303 will be the first time that we definitively in a randomized setting, evaluate zanidatamab versus what would be considered a standard of care. So we expect to be out ahead with important data that will inform decisions about whether to use zanidatamab or other HER2 agents in that space.

    asked by Jess Fye · answered by Robert Iannone

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Commercial Execution Drives Record Q1 Revenues

    Jazz Pharmaceuticals reported an exceptionally strong first quarter, achieving its highest ever first quarter total revenues of $1.1 billion, representing over 19% year-over-year growth. This performance was driven by robust commercial execution across its highly differentiated product portfolio, including Xywav, Epidiolex, Modeyso, and Zepzelca, all of which demonstrated double-digit growth. The company highlighted disciplined efforts by its commercial teams in supporting physicians and patients.

    02

    Zanidatamab Progress in HER2-positive GEA

    The company is urgently advancing zanidatamab for patients with HER2-positive first-line locally advanced or metastatic GEA, an area of significant unmet medical need. The FDA recently accepted the sBLA for Ziihera under real-time oncology review, granting Priority Review with a PDUFA date of August 25, 2026. Management expects Ziihera to become the HER2-targeted therapy of choice due to the magnitude of benefits observed in the HERIZON-GEA trial, including an unprecedented🌐 median overall survival of 26.4 months with the triplet arm.

    03

    Modeyso Launch Momentum and First-Line Potential

    Modeyso generated strong early net product sales of $41 million in Q1 2026, following its launch in August 2025. Approximately 500 patients have been treated with Modeyso since launch, reflecting the significant unmet need in H3 K27M-mutant diffuse midline glioma. The company sees potential upsides in treatment duration and patient population size, especially with the ongoing Phase III ACTION trial, which is designed to support regulatory approval for frontline therapy directly following radiation, potentially expanding the market and duration of treatment.

    04

    Zepzelca Growth Driven by Frontline Maintenance

    Zepzelca net product sales increased 60% year-over-year to $101 million in Q1 2026. This growth was primarily fueled by strong uptake in the frontline maintenance setting, following FDA approval in combination with Tecentriq in October of the prior year. Healthcare providers are rapidly adopting the Zepzelca combination due to the IMforte clinical data showing improved progression-free and overall survival for patients with extensive stage small cell lung cancer. While first-line maintenance adoption is expected to grow, second-line use is anticipated to decrease due to competition.

    05

    Pipeline Advancement Across Oncology and Neuroscience

    Jazz Pharmaceuticals continues to make progress across its pipeline with multiple clinical trials. Key oncology trials include ongoing registrational zanidatamab trials, such as the EmpowHER trial in metastatic breast cancer (enrollment completion H1 2027, data late 2027/early 2028) and a potentially registrational pan-tumor basket trial. In neuroscience and epilepsy, early-stage assets are in development, with the company actively exploring new mechanisms and building around its Epidiolex franchise.

    06

    Financial Strength and Strategic Capital Allocation

    The company reported a strong financial position with $2.9 billion in cash and investments and $408 million in cash from operations in Q1. This financial strength enables investment in commercial portfolio growth and pipeline advancement, alongside disciplined capital allocation for business development opportunities. Jazz is focused on expanding its presence in rare diseases, particularly strengthening existing areas like epilepsy, sleep, and rare oncology, and exploring new rare disease areas where it can leverage its capabilities.

    AI-generated summary of the company’s earnings call. Not investment advice.